长春胺缓释胶囊联合阿法舒眼液治疗前部缺血性视神经病变患者的临床疗效

doi:10.3760/cma.j.issn.1007-1245.2023.12.015

摘要/Abstract

摘要：

目的　观察长春胺缓释胶囊联合阿法舒眼液治疗前部缺血性视神经病变患者的临床疗效。方法　选取济宁普明眼科医院和济南市第二人民医院在2020年3月至2022年3月期间收治的118例前部缺血性视神经病变患者进行前瞻性研究，通过红蓝双色球法随机分为常规组（59例，64眼）和联合组（59例，64眼）。常规组男31例（35眼）、女28例（29眼），年龄51～60（55.78±4.20）岁，病程5～10（7.28±2.11）d，应用阿法舒眼液治疗；联合组男30例（34眼）、女29例（30眼），年龄51～61（55.82±4.31）岁，病程5～10（7.30±2.15）d，在常规组基础上口服长春胺缓释胶囊治疗。比较两组临床疗效和不良反应发生情况。统计学方法采用t检验与χ²检验。结果　与常规组相比，联合组总有效率更高［96.88%（62/64）比79.69%（51/64）］，差异有统计学意义（χ²=9.14，P<0.05）。治疗后，联合组的盘周神经纤维层和视网膜神经节细胞复合体厚度均低于常规组［（66.15±11.19）μm比（83.06±14.23）μm、（61.37±6.27）μm比（74.11±7.82）μm］，差异均有统计学意义（t=7.47、10.17，均P<0.05）。治疗后，联合组的60'P100 波潜时、15'P100 波潜时均低于常规组［（108.21±2.34）ms比（110.78±2.74）ms、（110.25±3.12）ms比（113.58±3.68）ms］，差异均有统计学意义（t=5.71、5.52，均P<0.05）；治疗后，联合组的60'P100 波振幅、15'P100 波振幅高于常规组［（5.21±1.07）μV比（4.23±1.02）μV、（6.79±1.26）μV比（5.38±1.14）μV］，差异均有统计学意义（t=4.82、6.64，均P<0.05）。治疗后，联合组的视野校正形态标准差、视野平均偏差均低于常规组［（3.34±0.38）比（3.72±0.42）、（-5.01±1.42）比（-6.54±1.59）］，差异均有统计学意义（t=5.37、5.74，均P<0.05）；治疗后，联合组的光敏感度、视力水平均高于常规组［（17.51±2.30）dB比（14.52±2.27）dB、（0.73±0.25）比（0.48±0.16）］，差异均有统计学意义（t=7.40、6.74，均P<0.05）。结论　长春胺缓释胶囊联合阿法舒眼液治疗前部缺血性视神经病变患者效果明显，能显著改善患者视野水平、视力水平、光敏感度和视觉诱发电位P100波振幅及潜时，降低盘周神经纤维层和视网膜神经节细胞复合体厚度，且安全性较高。

关键词:

前部缺血性视神经病变, 长春胺缓释胶囊, 阿法舒眼液, 光敏感度

Abstract:

Objective　To observe the clinical efficacy of vinblastine sustained-release capsules combined with brimonidine tartrate eye drops in the treatment of anterior ischemic optic neuropathy. Methods　A prospective study was conducted on 118 patients with anterior ischemic optic neuropathy admitted to Jining Puming Eye Hospital and Jinan Second People's Hospital from March 2020 to March 2022. They were randomly divided into a conventional group (59 cases with 64 eyes) and a combined group (59 cases with 64 eyes) by the red blue bicolor method. The routine group [31 men (35 eyes) and 28 women (29 eyes); 51-60 (55.78±4.20) years old; disease course 5-10 (7.28±2.11) days] were treated with brimonidine tartrate eye drops, and the combined group [30 men (34 eyes) and 29 women (30 eyes); 51-61 (55.82±4.31) years old; disease course 5-10 (7.30±2.15) days] with vinblastine sustained-release capsules and brimonidine tartrate eye drops. The clinical efficacies and incidences of adverse reactions of the two groups were compared. t and χ² tests were applied. Results　The total effective rate of the combined group was higher than that in the conventional group [96.88% (62/64) vs. 79.69% (51/64)], with a statistical difference (χ²=9.14, P<0.05). After the treatment, the thicknesses of peripheral nerve fiber layer and retinal ganglion cell complex in the combined group were lower than those in the conventional group [(66.15±11.19) μm vs. (83.06±14.23)μm and (61.37±6.27) μm vs. (74.11±7.82) μm], with statistical differences (t=7.473 and 10.17, both P<0.05). After the treatment, the 60'P100 and 15'P100 latencies in the combined group were lower than those in the conventional group [(108.21±2.34) ms vs. (110.78±2.74) ms and (110.25±3.12) ms vs. (113.58±3.68) ms], with statistical differences (t=5.71 and 5.52, both P<0.05). After the treatment, the amplitudes of 60'P100 and 15'P100 waves in the combined group were higher than those in the conventional group [(5.21±1.07)μV vs. (4.23±1.02) μV and (6.79±1.26) μV vs. (5.38±1.14) μV], with statistical differences (t=4.82 and 6.64, both P<0.05). After the treatment, the standard deviation of corrected visual field shape and the mean deviation of visual field in the combined group were significantly lower than those in the conventional group [(3.34±0.38) vs. (3.72±0.42) and (-5.01±1.42) vs. (-6.54±1.59)], with statistical differences (t=5.37 and 5.74, P<0.05). After the treatment, the light sensitivity and visual acuity of the combined group were significantly higher than those of the conventional group [(17.51±2.30) dB vs. (14.52±2.27) dB and (0.73±0.25) vs. (0.48±0.16)], with statistical differences (t=7.40 and 6.74, P<0.05). Conclusion　Vinblastine sustained-release capsules combined with brimonidine tartrate eye drops has obvious effect in the treatment of patients with anterior ischemic optic neuropathy, and can significantly improve their visual field, visual acuity, light sensitivity, and amplitude and latency of P100 wave of visual evoked potential and reduce the thickness of peripheral nerve fiber layer and retinal ganglion cell complex, with high safety.

Key words:

Anterior ischemic optic neuropathy, Vinblastine sustained-release capsules, Brimonidine tartrate eye drops, Light sensitivity

谷晨丁有舒毕超.

长春胺缓释胶囊联合阿法舒眼液治疗前部缺血性视神经病变患者的临床疗效 [J]. 国际医药卫生导报, 2023, 29(12): 1693-1697.

Gu Chen, Ding Youshu, Bi Chao.

Clinical efficacy of vincamine sustained-release capsules combined with brimonidine tartrate eye drops in treatment of anterior ischemic optic neuropathy [J]. International Medicine and Health Guidance News, 2023, 29(12): 1693-1697.

参考文献

[1] 乌日汗,刘丽娟,杨本涛,等.先天性视盘占位病变继发非动脉炎性前部缺血性视神经病变的临床特征分析[J].眼科,2020,29(2):141-146.DOI:10.13281/j.cnki.issn.1004- 4469. 2020.02.014.
[2] 李东丽,宫媛媛.间充质干细胞源性外泌体对前部缺血性视神经病变患者的治疗潜力[J].眼科新进展,2020,40(5):492-496.DOI:10.13389/j.cnki.rao.2020.0113.
[3] 廖飞,黄洪强,麦天帆.苦碟子注射液治疗前部缺血性视神经病变的临床效果观察[J].国际医药卫生导报,2014,20(21):3303-3305.DOI:10.3760/cma.j.issn.1007-1245. 2014.21.033.
[4] 袁志兰,孙红,王理理,等.国产酒石酸溴莫尼定滴眼液的降眼压作用[J].国际眼科杂志,2006,6(5):1066-1068.DOI:10.3969/j.issn.1672-5123.2006.05.028.
[5] 王银歌,王宝勇,张德才.葛根素葡萄糖注射液联合长春胺缓释胶囊治疗前部缺血性视神经病变的临床效果[J].药物评价研究,2021,44(1):116-121.DOI:10.7501/j.issn.1674- 6376.2021.01.015.
[6] 梁超群,陈长征,苏钰,等.长春胺缓释胶囊治疗非动脉炎性前部缺血性视神经病变的疗效及安全性[J].国际眼科杂志,2017,17(10):1845-1848.DOI:10.3980/j.issn.1672-5123. 2017.10.10.
[7] 中华医学会眼科学分会神经眼科学组.我国非动脉炎性前部缺血性视神经病变诊断和治疗专家共识(2015年)[J].中华眼科杂志,2015,51(5):323-326.DOI:10.3760/cma.j.issn.0412-4081.2015.05.002.
[8] 孙传兴.临床疾病诊断依据治愈好转标准[M].2版.北京:人民军医出版社,2002:583-584.
[9] 台金岭,赵宪孟,李月礼,等.玻璃体腔注射康柏西普和曲安奈德治疗非动脉炎性前部缺血性视神经病变的比较研究[J].现代药物与临床,2020,35(12):2400-2404.DOI:10.7501/j.issn.1674-5515.2020.12.023.
[10] 刘梅,郑艳霞.血府逐瘀汤加减联合针刺治疗急性前部缺血性视神经病变疗效及对视力、视野、视觉诱发电位的影响[J].现代中西医结合杂志,2021,30(24):2704-2707.DOI:10.3969/j.issn.1008-8849.2021.24.018.
[11] 陈文瑜,艾明,陈婷.糖皮质激素治疗非动脉炎性前部缺血性视神经病变的研究进展[J].中国医药,2022,17(3):477-480.DOI:10.3760/j.issn.1673-4777.2022.03.036.
[12] 岳军,吴媛媛,李勤英,等.舒肝解郁通络汤对前部缺血性视神经病变患者视力、眼血流动力学及PVEP的影响[J].中医药信息,2020,37(3):84-87.DOI:10.19656/j.cnki.1002-2406.200079.
[13] 裴超,邵霖霖,刘晶,等.中西医结合治疗非动脉炎性前部缺血性视神经病变临床疗效Meta分析[J].中国中医眼科杂志,2020,30(3):221-226.DOI:10.13444/j.cnki.zgzyykzz. 2020.03.019.
[14] 陈凯,周洪伟.神经生长因子治疗非动脉炎性前部缺血性视神经病变的临床效果[J].中华眼视光学与视觉科学杂志,2020,22(10):781-785.DOI:10.3760/cma.j.cn115909- 20191228-00353.
[15] 孙婉钰,廖星,王影,等.糖皮质激素类药物治疗非动脉炎性前部缺血性视神经病变有效性的系统评价[J].中华眼底病杂志,2021,37(3):224-230.DOI:10.3760/cma.j.cn511434- 20200114-00017.
[16] 付梦军,张浩润,王锐,等.0.2%酒石酸溴莫尼定滴眼液在改善近视患者屈光手术后夜间视觉质量的研究[J].临床眼科杂志,2012,20(3):229-231.DOI:10.3969/j.issn.1006- 8422.2012.03.013.
[17] 蔡金玲,郭玉兰,刘磊.复明片联合长春胺治疗青光眼的价值评估[J].河北医药,2019,41(12):1801-1804.DOI:10.3969/j.issn.1002-7386.2019.12.009.
[18] 侯恩太,李多伟.小蔓长春花中长春胺药学研究进展[J].西北药学杂志,2010,25(4):314-316.DOI:10.3969/j.issn.1004-2407.2010.04.043.
[19] 王迎彬,陈梦平,赵宏.长春胺缓释胶囊联合小牛血去蛋白提取物治疗前部缺血性视神经病变的疗效观察[J].现代药物与临床,2019,34(7):2111-2114.DOI:10.7501/j.issn.1674-5515.2019.07.039.
[20] 郭金喜,刁科,张晓娜,等.前部缺血性视神经病变患者图形视觉诱发电位与视功能改变的关系及其临床意义[J].现代生物医学进展,2020,20(15):2975-2978.DOI:10.13241/j.cnki.pmb.2020.15.036.
[21] 周歆,任美侠,闵捷,等.非动脉炎性前部缺血性视神经病变患者的明适应负向波变化特点分析[J].眼科新进展,2020,40(4):373-376,384.DOI:10.13389/j.cnki.rao.2020.0086.
[22] 董宁,SIHAM ALMANSOOB,高玲.糖尿病患者视网膜神经节细胞复合体和神经纤维层厚度的变化[J].中国动脉硬化杂志,2020,28(8):651-657.DOI:10.3969/j.issn.1007-3949. 2020.08.003.
[23] Augstburger E,Ballino A,Keilani C,et al.Follow-up of nonarteritic anterior ischemic optic neuropathy with optical coherence tomography angiography[J].Invest Ophthalmol Vis Sci,2021,62(2):42.DOI:10.1167/iovs.62.4.42.
[24] 肖玥言,魏文斌,王亚星,等.非动脉炎性前部缺血性视神经病变患者的血液流变学改变[J].眼科,2018,27(2):154-156.DOI:10.13281/j.cnki.issn.1004-4469.2018.02.016.
[25] 关怀英,孔凡宏,张大卫,等.血栓通对非动脉炎性前部缺血性视神经病变患者视力、视野改善效果及作用机制分析[J].中国煤炭工业医学杂志,2018,21(1):6-10.DOI:10.11723/mtgyyx1007-9564201801002.
[26] 朱丽平,赖春涛,杨庆林,等.以前部缺血性视神经病变为表现的白塞病相关视神经病的临床分析[J].中华眼科杂志,2019,55(3):203-207.DOI:10.3760/cma.j.issn.0412-4081. 2019.03.009.
[27] 杨旭,孙世龙,楚金亭,等.高压氧治疗非动脉炎性前部缺血性视神经病变的疗效观察[J].中华物理医学与康复杂志,2019,41(11):829-832.DOI:10.3760/cma.j.issn.0254- 1424.2019.11.006.
[28] 吴子旭,郑东萍,潘陆平.非动脉炎性前部缺血性视神经病变患者临床特征和视盘形态分析[J].中国药物与临床,2018,18(9):1490-1492.DOI:10.11655/zgywylc2018. 09.008.
[29] 田国红.福祸相依——1例药物诱发的非动脉炎性前部缺血性视神经病变[J].中国眼耳鼻喉科杂志,2019,19(4):293-294.DOI:10.14166/j.issn.1671-2420.2019.04.020.
[30] 邹文军,武志峰,张洁,等.非动脉炎性前部缺血性视神经病变患眼视盘周围及黄斑区视网膜血流参数变化特征[J].中华眼视光学与视觉科学杂志,2018,20(12):737-742.DOI:10.3760/cma.j.issn.1674-845X.2018.12.007.